Genscript Biotech

Genscript Biotech Gross Profit

The Gross Profit of Genscript Biotech (1548.HK) as of Nov 6, 2026 is 553.20 M USD. In the previous year, Gross Profit was 34.69 M USD — a change of 1,494.48% (higher).

Gross Profit

553.20 MUSD

YoY

1,494.48%

Last updated:

Gross Profit of Genscript Biotech is 2025 553.20 M USD. Gross Profit of Genscript Biotech was 2024 34.69 M USD. It decreases by 1,494.48% higher compared to the previous year.

The Genscript Biotech Gross Profit history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Profit
Date
Gross Profit
Jan 1, 2018
158.54 M USD
Jan 1, 2019
180.29 M USD
Jan 1, 2020
255.89 M USD
Jan 1, 2021
303.48 M USD
Jan 1, 2022
38.77 M USD
Jan 1, 2023
34.50 M USD
Jan 1, 2024
34.69 M USD
Jan 1, 2025
553.20 M USD
The Genscript Biotech Gross Profit history
YEARGross ProfitYoY
553.20 MUSD+1,494.48%
34.69 MUSD+0.55%
34.50 MUSD-11.00%
38.77 MUSD-87.23%
303.48 MUSD+18.60%
255.89 MUSD+41.93%
180.29 MUSD+13.72%
158.54 MUSD+51.58%
104.59 MUSD+37.21%
76.23 MUSD+33.55%
57.08 MUSD+29.43%
44.10 MUSD+15.64%
38.13 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genscript Biotech Revenue

Genscript Biotech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
75.79 M USD
1.18 M USD
377.63 M USD
Jan 1, 2025
959.53 M USD
255.25 M USD
-532.83 M USD
Jan 1, 2026 (e)
893.85 M USD
55.75 M USD
28.41 M USD
Jan 1, 2027 (e)
1.18 B USD
285.04 M USD
199.23 M USD
Jan 1, 2028 (e)
1.49 B USD
495.14 M USD
350.69 M USD
Jan 1, 2029 (e)
1.08 B USD
123.42 M USD
0.00 USD
Jan 1, 2030 (e)
1.18 B USD
145.86 M USD
0.00 USD
Jan 1, 2031 (e)
1.29 B USD
0.00 USD
0.00 USD

Genscript Biotech Margins

Genscript Biotech stock margins

The Genscript Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Genscript Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Genscript Biotech.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
45.77 %
1.56 %
498.22 %
Jan 1, 2025
57.65 %
26.60 %
-55.53 %
Jan 1, 2026 (e)
57.65 %
6.24 %
3.18 %
Jan 1, 2027 (e)
57.65 %
24.10 %
16.85 %
Jan 1, 2028 (e)
57.65 %
33.18 %
23.50 %
Jan 1, 2029 (e)
57.65 %
11.41 %
0.00 %
Jan 1, 2030 (e)
57.65 %
12.31 %
0.00 %
Jan 1, 2031 (e)
57.65 %
0.00 %
0.00 %

Genscript Biotech Stock analysis

What does Genscript Biotech do? GenScript Biotech Corp. is a leading biotechnology company founded in Nanjing, China in 2002. Today, it is headquartered in New Jersey, USA and operates worldwide. Genscript Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genscript Biotech stock

Gross Profit of Genscript Biotech is 553.20 M USD in 2025.

Gross Profit of Genscript Biotech changed from 34.69 M USD to 553.20 M USD, representing a 1,494.48% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Profit Genscript Biotech since 2006 – with annual values, charts, and detailed analysis.

Gross Profit is the revenue remaining after deducting the cost of goods sold. It shows how efficiently a company uses its resources to produce goods or services.

Gross Profit's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Gross Profit's Genscript Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Genscript Biotech

All Key Metrics — Genscript Biotech